CenturyLink Investment Management Co maintained its stake in Eli Lilly and Co. (NYSE:LLY) during the third quarter, Holdings Channel reports. The fund owned 26,610 shares of the company’s stock at the end of the third quarter. CenturyLink Investment Management Co’s holdings in Eli Lilly and were worth $2,136,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Iowa State Bank bought a new stake in Eli Lilly and during the second quarter valued at approximately $104,000. PineBridge Investments L.P. raised its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the period. Cribstone Capital Management LLC bought a new stake in Eli Lilly and during the second quarter valued at approximately $117,000. Coconut Grove Bank raised its stake in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock valued at $122,000 after buying an additional 50 shares during the period. Finally, Physicians Financial Services Inc. raised its stake in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares during the period. 73.93% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and Co. (NYSE:LLY) traded down 0.04% during midday trading on Wednesday, hitting $67.12. The stock had a trading volume of 9,085,308 shares. The stock has a 50-day moving average price of $75.39 and a 200-day moving average price of $77.74. Eli Lilly and Co. has a 12-month low of $64.18 and a 12-month high of $88.16. The stock has a market cap of $70.99 billion, a P/E ratio of 29.20 and a beta of 0.28.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. Equities analysts forecast that Eli Lilly and Co. will post $3.55 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is currently 88.70%.

ILLEGAL ACTIVITY WARNING: This news story was first published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The original version of this news story can be read at http://www.financial-market-news.com/eli-lilly-and-co-lly-position-held-by-centurylink-investment-management-co/1211342/.

Several research firms recently commented on LLY. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a report on Monday, October 3rd. Jefferies Group reiterated a “buy” rating and set a $100.00 price target (down previously from $105.00) on shares of Eli Lilly and in a research report on Friday, October 28th. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. JPMorgan Chase & Co. upgraded Eli Lilly and from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $92.00 to $95.00 in a research report on Thursday, September 8th. Finally, Leerink Swann reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research report on Sunday, October 9th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Eli Lilly and has a consensus rating of “Buy” and an average price target of $108.34.

In related news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the sale, the insider now owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.